New drug targets in atopic dermatitis

Simon, Dagmar; Simon, Hans-Uwe (2012). New drug targets in atopic dermatitis. Chemical immunology and allergy, 96, pp. 126-131. Basel: Karger

Full text not available from this repository.

Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by eczematous skin lesions, pruritus and typical histopathological features. T cells are thought to play a key role, but B cells might also participate in the pathogenesis of AD. In two investigator-initiated pilot studies, we studied the effects of B cell depletion by monoclonal anti-CD20 antibody therapy or a reduction of activated T cells by LFA3-IgG fusion protein on moderate-to-severe AD. All patients treated with either rituximab or alefacept showed an improvement of their skin symptoms with a sustained effect after treatment. In both studies, histological alterations, such as spongiosis, acanthosis and dermal infiltrate, including T and B cell numbers, dramatically improved and the expression of IL-5 and IL-13 was reduced after therapy. Upon rituximab therapy, allergen-specific IgE levels were not altered and total serum IgE levels only slightly decreased. According to recent studies, neutralizing B and T cells products such as IgE or IL-5 might be effective in subgroups of patients with AD.

Item Type:	Journal Article (Further Contribution)
Division/Institute:	04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology 04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology
UniBE Contributor:	Simon, Dagmar, Simon, Hans-Uwe
ISSN:	1660-2242
Publisher:	Karger
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 14:35
Last Modified:	05 Dec 2022 14:11
PubMed ID:	22433382
Web of Science ID:	000304075400019
URI:	https://boris.unibe.ch/id/eprint/14110 (FactScience: 220920)